Vpr Enhances HIV-1 Env Processing and Virion Infectivity in Macrophages by Modulating TET2-Dependent IFITM3 Expression
Open accessThe DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
How Vpr enhances HIV-1 replication in macrophages is still unclear. We report here that Vpr enhanced HIV-1 Env processing during the first round of HIV-1 replication, resulting in virions with higher Env incorporation and viral infectivity. These higher-quality viral particles contributed to elevated infection during the second round and spreading infection in macrophages and other HIV-1 target cells. We have recently discovered that TET2 is a novel host factor degraded by Vpr, which leads to sustained IL-6 expression in macrophages. Interestingly, Vpr-enhanced HIV-1 Env processing depended on both the IFITIM3 and TET2 genes. The constitutive expression of IFITIM3 expression in macrophages was maintained by TET2, which demethylated the IFITIM3 promoter. We conclude that the Vpr degrades TET2 to enhance HIV-1 replication in macrophages by reducing IFITIM3 expression to increase viral Env processing, virion incorporation, and infectivity and by sustaining IL-6 expression to increase HIV-1 gene expression. The Vpr-TET2 axis may serve as a novel target to develop anti-HIV drugs to inhibit HIV-1 infection and pathogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“By targeting PU.1, Vpr systemically disrupted several antiviral factors, including MRC1, and IFITM3, a previously reported target of Vpr that is also capable of disrupting Env function38.”
From HIV-1 Vpr combats the PU.1-driven antiviral response in primary human macrophages (2024) · cites this paper as [38]
The cited source says what the claim attributes to it.
In the citing paper
“During HIV-1 infection of macrophages, in the absence of Vpr, TET2 demethylates the IFITM3 promoter, relieving suppression, contributing to the antiviral response.”
From HIV-1 Vpr combats the PU.1-driven antiviral response in primary human macrophages (2024) · cites this paper as [38]
The cited source says what the claim attributes to it.
In the citing paper
“Two of these genes, MRC1 and IFITM3, inhibit the spread of HIV in MDMs by targeting HIV-1 Env35,38.”
From HIV-1 Vpr combats the PU.1-driven antiviral response in primary human macrophages (2024) · cites this paper as [38]
The cited source says what the claim attributes to it.
In the citing paper
“IFITM3 expression is regulated by the DNA dioxygenase, TET238.”
From HIV-1 Vpr combats the PU.1-driven antiviral response in primary human macrophages (2024) · cites this paper as [38]
The cited source says what the claim attributes to it.
In the citing paper
“To prevent this, Vpr mediates the ubiquitylation and degradation of TET2, which in turn inhibits IFITM3 expression.”
From HIV-1 Vpr combats the PU.1-driven antiviral response in primary human macrophages (2024) · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1
Tahiliani, M., Koh, K. P., Shen, Y., Pastor, W. A., Bandukwala, H., Brudno, Y., Agarwal, S., Iyer, L. M., Liu, D. R., Aravind, L., et al. (2009) · Science · doi:10.1126/science.1170116 · Cited by 5,836 · cited 1×
“TET methylcytosine dioxygenases (TET1, -2, and -3 in mammalian cells [18, 19]) catalyze three steps of iterative oxidation, first converting 5mC to 5-hydroxymethyl cytosine (5hmC), then 5hmC to 5-formyl cytosine (5fC), and finally 5fC to 5-carboxy cytosine (5caC).”
Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine
Ito, S., Shen, L., Dai, Q., Wu, S. C., Collins, L. B., Swenberg, J. A., He, C., & Zhang, Y. (2011) · Science · doi:10.1126/science.1210597 · Cited by 3,451
DNA methylation landscapes: Provocative insights from epigenomics
Suzuki, M. M., & Bird, A. (2008) · Nature Reviews Genetics · doi:10.1038/nrg2341 · Cited by 3,039
The Nuclear DNA Base 5-Hydroxymethylcytosine Is Present in Purkinje Neurons and the Brain
Kriaucionis, S., & Heintz, N. (2009) · Science · doi:10.1126/science.1169786 · Cited by 2,700
HIV Infection, Inflammation, Immunosenescence, and Aging
Deeks, S. G. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-042909-093756 · Cited by 1,349
Connor, R. I., Chen, B. K., Choe, S., & Landau, N. R. (1995) · Virology · doi:10.1006/viro.1995.1016 · Cited by 1,253
Heinzinger, N. K., Bukinsky, M. I., Haggerty, S. A., Ragland, A. M., Kewalramani, V, Lee, M. A., Gendelman, H. E., Ratner, L., Stevenson, M., & Emerman, M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.15.7311 · Cited by 854 · cited 1×
“Although macrophages are relatively resistant to HIV-1 infection compared to activated CD4 T cells (2), HIV-1 has evolved to efficiently infect macrophages, which is enhanced by HIV-1 viral proteins such as viral protein R (Vpr) to counteract macrophage-specific restrictions (3, 4).”
The broad-spectrum antiviral functions of IFIT and IFITM proteins
Diamond, M. S., & Farzan, M. (2013) · Nature Reviews Immunology · doi:10.1038/nri3344 · Cited by 849
Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6
Zhang, Q., Zhao, K., Shen, Q., Han, Y., Gu, Y., Li, X., Zhao, D., Liu, Y., Wang, C., Zhang, X., et al. (2015) · Nature · doi:10.1038/nature15252 · Cited by 807 · cited 12×
“The TET2-IFITM3 axis in MDMs thus suppresses HIV-1 replication both at the Env processing/virion infectivity step and possibly at the viral entry step in cells previously exposed to Vpr. IFITM3 expression is regulated by DNA methylation at the IFITM3 promoter (46).”
InfluentialIgarashi, T., Brown, C. R., Endo, Y., Buckler-White, A., Plishka, R., Bischofberger, N., Hirsch, V., & Martin, M. A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.2.658 · Cited by 361
WT1 Recruits TET2 to Regulate Its Target Gene Expression and Suppress Leukemia Cell Proliferation
Wang, Y., Xiao, M., Chen, X., Chen, L., Xu, Y., Lv, L., Wang, P., Yang, H., Ma, S., Lin, H., et al. (2015) · Molecular Cell · doi:10.1016/j.molcel.2014.12.023 · Cited by 304
Guanylate Binding Protein (GBP) 5 Is an Interferon-Inducible Inhibitor of HIV-1 Infectivity
Krapp, C., Hotter, D., Gawanbacht, A., McLaren, P. J., Kluge, S. F., Stürzel, C. M., Mack, K., Reith, E., Engelhart, S., Ciuffi, A., et al. (2016) · Cell Host & Microbe · doi:10.1016/j.chom.2016.02.019 · Cited by 256
Balliet, J. W., Kolson, D. L., Eiger, G., Kim, F. M., McGann, K. A., Srinivasan, A., & Collman, R. (1994) · Virology · doi:10.1006/viro.1994.1225 · Cited by 236
Importance of vpr for infection of rhesus monkeys with simian immunodeficiency virus
Lang, S. M., Weeger, M., Stahl-Hennig, C., Coulibaly, C., Hunsmann, G., Müller, J., Müller-Hermelink, H., Fuchs, D., Wachter, H., & Daniel, M. M. (1993) · Journal of Virology · doi:10.1128/jvi.67.2.902-912.1993 · Cited by 221 · cited 3×
“The functional importance of Vpr was first reported in rhesus macaques infected with Vpr-deficient simian immunodeficiency virus (SIV) (5).”
InfluentialLaguette, N., Brégnard, C., Hue, P., Basbous, J., Yatim, A., Larroque, M., Kirchhoff, F., Constantinou, A., Sobhian, B., & Benkirane, M. (2014) · Cell · doi:10.1016/j.cell.2013.12.011 · Cited by 212
Allen, E. K., Randolph, A. G., Bhangale, T., Dogra, P., Ohlson, M., Oshansky, C. M., Zamora, A. E., Shannon, J. P., Finkelstein, D., Dressen, A., et al. (2017) · Nature Medicine · doi:10.1038/nm.4370 · Cited by 193
HIV-1 Vpr-Mediated G2 Arrest Involves the DDB1-CUL4AVPRBP E3 Ubiquitin Ligase
Belzile, J.-P., Duisit, G., Rougeau, N., Mercier, J., Finzi, A., & Cohen, É. A. (2007) · PLoS Pathogens · doi:10.1371/journal.ppat.0030085 · Cited by 189 · cited 1×
“Vpr has two widely studied activities: one is its ability to induce G2 cell cycle arrest, and the other is to increase HIV-1 replication in macrophages (32, 33).”
Resistance of Transmitted Founder HIV-1 to IFITM-Mediated Restriction
Foster, T. L., Wilson, H., Iyer, S. S., Coss, K., Doores, K., Smith, S., Kellam, P., Finzi, A., Borrow, P., Hahn, B. H., et al. (2016) · Cell Host & Microbe · doi:10.1016/j.chom.2016.08.006 · Cited by 171
IFITM Proteins Restrict HIV-1 Infection by Antagonizing the Envelope Glycoprotein
Yu, J., Li, M., Wilkins, J., Ding, S., Swartz, T. H., Esposito, A. M., Zheng, Y.-M., Freed, E. O., Liang, C., Chen, B. K., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.08.055 · Cited by 170
Macrophages and HIV-1: An Unhealthy Constellation
Sattentau, Q. J., & Stevenson, M. (2016) · Cell Host & Microbe · doi:10.1016/j.chom.2016.02.013 · Cited by 167
Chen, R., Rouzic, E. L., Kearney, J. A., Mansky, L. M., & Bénichou, S. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m403875200 · Cited by 157
Eckstein, D. A., Sherman, M. P., Penn, M. L., Chin, P. S., De Noronha, C. M. C., Greene, W. C., & Goldsmith, M. A. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.10.1407 · Cited by 124
Aldrovandi, G. M., & Zack, J. A. (1996) · Journal of Virology · doi:10.1128/jvi.70.3.1505-1511.1996 · Cited by 118
Zhang, S., Feng, Y., Narayan, O., & Zhao, L.-J. (2001) · Gene · doi:10.1016/s0378-1119(00)00583-7 · Cited by 106 · cited 1×
“Vpr is believed to facilitate HIV-1 replication through its interaction with VprBP (9), a most abundant CUL4 binding partner first discovered by its binding with Vpr (also known as DCAF1) (10, 11).”
Ahn, J., Vu, T., Novince, Z., Guerrero-Santoro, J., Rapic-Otrin, V., & Gronenborn, A. M. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.133181 · Cited by 104
Jacquot, G., Rouzic, E. L., David, A., Mazzolini, J., Bouchet, J., Bouaziz, S., Niedergang, F., Pancino, G., & Bénichou, S. (2007) · Retrovirology · doi:10.1186/1742-4690-4-84 · Cited by 103
Bobadilla, S., Sunseri, N., & Landau, N. R. (2013) · Gene Therapy · doi:10.1038/gt.2012.61 · Cited by 103
Dedera, D., Hu, W., Vander Heyden, N., & Ratner, L. (1989) · Journal of Virology · doi:10.1128/jvi.63.7.3205-3208.1989 · Cited by 100
Lv, L., Wang, Q., Xu, Y., Tsao, L.-C., Nakagawa, T., Guo, H., Su, L., & Xiong, Y. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.05.007 · Cited by 100
Self-citationLatent HIV-1 Infection of Resting CD4 + T Cells in the Humanized Rag2 −/− γ c −/− Mouse
Choudhary, S. K., Archin, N. M., Cheema, M., Dahl, N., García, J. V., & Margolis, D. M. (2011) · Journal of Virology · doi:10.1128/jvi.05590-11 · Cited by 88
McCall, C. M., Miliani de Marval, P. L., Chastain, P. D., Jackson, S. C., He, Y. J., Kotake, Y., Cook, J. G., & Xiong, Y. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00232-08 · Cited by 83
The role of matrix in HIV-1 envelope glycoprotein incorporation
Tedbury, P. R., & Freed, E. O. (2014) · Trends in Microbiology · doi:10.1016/j.tim.2014.04.012 · Cited by 77
Rab7A Is Required for Efficient Production of Infectious HIV-1
Caillet, M., Janvier, K., Pelchen–Matthews, A., Delcroix-Genête, D., Camus, G., Marsh, M., & Berlioz‐Torrent, C. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1002347 · Cited by 77
Vpr Overcomes Macrophage-Specific Restriction of HIV-1 Env Expression and Virion Production
Mashiba, M., Collins, D. R., Terry, V. H., & Collins, K. L. (2014) · Cell Host & Microbe · doi:10.1016/j.chom.2014.10.014 · Cited by 71 · cited 3×
“In agreement with other studies (6), we found Vpr did not enhance HIV-1 virion production in the first-round infection in MDMs but enhanced HIV-1 Env processing to produce more infectious HIV-1 virions for the second-round infection (Fig.”
InfluentialTartour, K., Nguyen, X.-N., Appourchaux, R., Assil, S., Barateau, V., Bloyet, L.-M., Burlaud Gaillard, J., Confort, M.-P., Escudero-Perez, B., Gruffat, H., et al. (2017) · PLOS Pathogens · doi:10.1371/journal.ppat.1006610 · Cited by 69
Processing and routage of HIV glycoproteins by furin to the cell surface
Moulard, M., Hallenberger, S., Garten, W., & Klenk, H. (1999) · Virus Research · doi:10.1016/s0168-1702(99)00002-7 · Cited by 66
Romani, B., Shaykh Baygloo, N., Aghasadeghi, M. R., & Allahbakhshi, E. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.641522 · Cited by 63
Lentivirus Vpr and Vpx accessory proteins usurp the cullin4–DDB1 (DCAF1) E3 ubiquitin ligase
Romani, B., & Cohen, É. A. (2012) · Current Opinion in Virology · doi:10.1016/j.coviro.2012.09.010 · Cited by 63 · cited 4×
“Vpr is believed to facilitate HIV-1 replication through its interaction with VprBP (9), a most abundant CUL4 binding partner first discovered by its binding with Vpr (also known as DCAF1) (10, 11).”
InfluentialThe cell biology of HIV-1 and other retroviruses
Freed, E. O., & Mouland, A. J. (2006) · Retrovirology · doi:10.1186/1742-4690-3-77 · Cited by 60
Igarashi, T. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.021551798 · Cited by 57
Sato, K., Misawa, N., Iwami, S., Satou, Y., Matsuoka, M., Ishizaka, Y., Ito, M., Aihara, K., An, D. S., & Koyanagi, Y. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003812 · Cited by 56
Characterization of a thymus-tropic HIV-1 isolate from a rapid progressor: role of the envelope
Meissner, E. G., Duus, K. M., Gao, F., Yu, X.-F., & Su, L. (2004) · Virology · doi:10.1016/j.virol.2004.07.019 · Cited by 50
Self-citation90K, an interferon-stimulated gene product, reduces the infectivity of HIV-1
Lodermeyer, V., Suhr, K., Schrott, N., Kolbe, C., Stürzel, C. M., Krnavek, D., Münch, J., Dietz, C., Waldmann, T., Kirchhoff, F., et al. (2013) · Retrovirology · doi:10.1186/1742-4690-10-111 · Cited by 50
Vpr Promotes Macrophage-Dependent HIV-1 Infection of CD4+ T Lymphocytes
Collins, D. R., Lubow, J., Lukic, Z., Mashiba, M., & Collins, K. L. (2015) · PLOS Pathogens · doi:10.1371/journal.ppat.1005054 · Cited by 34
HIV-1 Viral Protein R (VPR) and its Interactions with Host Cell
Li, G., Bukrinsky, M., & Zhao, Y. (2009) · Current HIV Research · doi:10.2174/157016209787581436 · Cited by 33
Miller, E. D., Duus, K., Townsend, M. B., Yi, Y., Collman, R. G., Reitz, M. S., & Su, L. (2001) · Journal of Virology · doi:10.1128/jvi.75.18.8498-8506.2001 · Cited by 29
Self-citationHIV-1 Envelope Glycoprotein at the Interface of Host Restriction and Virus Evasion
Beitari, S., Wang, Y., Liu, S., & Liang, C. (2019) · Viruses · doi:10.3390/v11040311 · Cited by 27
Ye, C., Wang, W., Cheng, L., Li, G., Wen, M., Wang, Q., Zhang, Q., Li, D., Zhou, P., & Su, L. (2016) · Journal of Virology · doi:10.1128/jvi.01389-16 · Cited by 23
Self-citationUnderstanding the molecular manipulation of DCAF1 by the lentiviral accessory proteins Vpr and Vpx
Cassiday, P. A., DePaula-Silva, A. B., Chumley, J., Ward, J. P., Barker, E., & Planelles, V. (2014) · Virology · doi:10.1016/j.virol.2014.11.024 · Cited by 14
Kao, S., Miller, E. D., & Su, L. (2001) · Virology · doi:10.1006/viro.2001.1112 · Cited by 11
Self-citationMisra, A., Gleeson, E. I., Wang, W., Ye, C., Zhou, P., & Kimata, J. T. (2018) · Journal of Virology · doi:10.1128/jvi.02080-17 · Cited by 10
Cited by
Pharmacological perspectives and molecular mechanisms of coumarin derivatives against virus disease
Li, Z., Kong, D., Liu, Y., & Li, M. (2021) · Genes & Diseases · doi:10.1016/j.gendis.2021.03.007 · Cited by 70
Vpr and Its Cellular Interaction Partners: R We There Yet?
Fábryová, H., & Strebel, K. (2019) · Cells · doi:10.3390/cells8111310 · Cited by 56
Wang, Y., Sholeh, M., Yang, L., Shakourzadeh, M. Z., Beig, M., & Azizian, K. (2025) · Antimicrobial Resistance and Infection Control · doi:10.1186/s13756-025-01518-5 · Cited by 52
Macrophages: Key Cellular Players in HIV Infection and Pathogenesis
Woottum, M., Yan, S., Sayettat, S., Grinberg, S., Cathelin, D., Bekaddour, N., Herbeuval, J., & Bénichou, S. (2024) · Viruses · doi:10.3390/v16020288 · Cited by 42
Yu, Y., Yan, R., Chen, X., Sun, T., & Yan, J. (2020) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-020-03865-w · Cited by 38
Metadata
- Authors
- Wang, Q., & Su, L.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Su, Lishan
- ORCID
- Su, Lishan
- Venue
- mBio
- Publisher
- American Society for Microbiology
- Published
- 2019-08-27
- Volume
- 10
- Issue
- 4
- ISSN
- 2150-7511 (ISSN-L)
- 2161-2129
- PMC
- PMC6703422
- OpenAlex
- W2969404469
- Cited by
- 34
- References
- 51
- Citations by year
- 2026: 5 · 2025: 3 · 2024: 6 · 2023: 1 · 2022: 7 · 2021: 6 · 2020: 4 · 2019: 2
- FWCI
- 2.66
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (vor)
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- mBio (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- UNC Libraries
- Funders
- HHS | National Institutes of Health (AI127346, AI136990)
- Topics
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and Retrovirus Studies
- Keywords
- HIV-1 Vpr, TET2, IFITM3, viral infectivity, macrophages, viral assembly, interleukin-6, promoter demethylation, host factors, HIV-1 replication, anti-HIV drug targets
- MeSH terms
- DNA Demethylation, Carrier Proteins, Cell Line, DNA-Binding Proteins, Humans, Macrophages, Membrane Proteins, Promoter Regions, Genetic, Proto-Oncogene Proteins, Virion, Virus Replication, HIV-1, Interleukin-6, Gene Expression Regulation, Viral, RNA-Binding Proteins, Anti-HIV Agents, Dioxygenases, env Gene Products, Human Immunodeficiency Virus, vpr Gene Products, Human Immunodeficiency Virus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.